Fouad's mailing address filed with the SEC is C/O NKARTA, INC., 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 4 years, insiders at Nkarta have traded over 2,620,353$ worth of Nkarta stock and bought 14,255,554 units worth 205,999,973$ . The most active insiders traders include Plc Gsk、Ali Behbahani、Holdings A/S Novo. On average, Nkarta executives and independent directors trade stock every 24 days with the average trade being worth of 1,501,195$. The most recent stock trade was executed by Alicia J. Hager on 16 July 2024, trading 3,396 units of NKTX stock currently worth 27,168$.
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Nkarta executives and other stock owners filed with the SEC include: